Want to join the conversation?
$IFF 2Q15 Call: Currency neutral sales improved 5%, including approx. 1 percentage point relating to the acquisition of Ottens Flavors. Top line performance continued to be driven by new wins. Adjusted operating profit on a currency neutral basis grew 7% as IFF achieved GM expansion. Currency neutral adjusted EPS improved by 10%.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.